KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Other Non-Current Assets: 2009-2025

Historic Other Non-Current Assets for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Sep 2025 value amounting to $103.1 million.

  • Jazz Pharmaceuticals' Other Non-Current Assets rose 37.00% to $103.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $103.1 million, marking a year-over-year increase of 37.00%. This contributed to the annual value of $114.5 million for FY2024, which is 69.69% up from last year.
  • As of Q3 2025, Jazz Pharmaceuticals' Other Non-Current Assets stood at $103.1 million, which was down 15.01% from $121.3 million recorded in Q2 2025.
  • In the past 5 years, Jazz Pharmaceuticals' Other Non-Current Assets registered a high of $121.3 million during Q2 2025, and its lowest value of $30.4 million during Q1 2021.
  • Its 3-year average for Other Non-Current Assets is $86.0 million, with a median of $75.2 million in 2024.
  • In the last 5 years, Jazz Pharmaceuticals' Other Non-Current Assets slumped by 35.57% in 2021 and then surged by 199.46% in 2022.
  • Quarterly analysis of 5 years shows Jazz Pharmaceuticals' Other Non-Current Assets stood at $40.8 million in 2021, then surged by 35.10% to $55.1 million in 2022, then increased by 22.35% to $67.5 million in 2023, then skyrocketed by 69.69% to $114.5 million in 2024, then surged by 37.00% to $103.1 million in 2025.
  • Its Other Non-Current Assets stands at $103.1 million for Q3 2025, versus $121.3 million for Q2 2025 and $116.5 million for Q1 2025.